UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rho kinase inhibition in diabetic nephropathy

Current opinion in nephrology and hypertension, 2011-01, Vol.20 (1), p.77-83

Komers, Radko

2011

Volltextzugriff (PDF)

miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7

Clinical science (1979), 2015-12, Vol.129 (12), p.1237-1249

2015

Volltextzugriff (PDF)

Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo

American journal of physiology. Renal physiology, 2012-08, Vol.303 (3), p.F377-F385

2012

Volltextzugriff (PDF)

An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis

Clinical journal of the American Society of Nephrology, 2018-03, Vol.13 (3), p.414-421

2018

Volltextzugriff (PDF)

Rho kinase inhibition in diabetic kidney disease

British journal of clinical pharmacology, 2013-10, Vol.76 (4), p.551-559

Komers, Radko

2013

Volltextzugriff (PDF)

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis

Kidney international reports, 2020-04, Vol.5 (4), p.494-502

2020

Volltextzugriff (PDF)

Paradoxes of nitric oxide in the diabetic kidney

American journal of physiology. Renal physiology, 2003-06, Vol.284 (6), p.F1121-F1137

2003

Volltextzugriff (PDF)

Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease

American journal of physiology. Regulatory, integrative and comparative physiology, 2016-05, Vol.310 (10), p.R877-R884

2016

Volltextzugriff (PDF)

Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure

Kidney international, 2011-02, Vol.79 (4), p.432-442

2011

Volltextzugriff (PDF)

Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety

Kidney medicine, 2024-06, Vol.6 (6), p.100833-100833, Article 100833

2024

Volltextzugriff (PDF)

Enhanced phosphorylation of Na(+)-Cl- co-transporter in experimental metabolic syndrome: role of insulin

Clinical science (1979), 2012-12, Vol.123 (11), p.635-647

2012

Volltextzugriff (PDF)

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

Kidney international reports, 2023-05, Vol.8 (5), p.1043-1056

2023

Volltextzugriff (PDF)

Pathophysiology of the Diabetic Kidney

Comprehensive Physiology, 2011-07, Vol.1 (3), p.1175-1232

2011

Volltextzugriff (PDF)

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)

Kidney international reports, 2017-07, Vol.2 (4), p.654-664

2017

Volltextzugriff (PDF)

Renin inhibition in the treatment of diabetic kidney disease

Clinical science (1979), 2013-05, Vol.124 (9), p.553-566

Komers, Radko

2013

Volltextzugriff (PDF)

Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment

PloS one, 2014-05, Vol.9 (5), p.e96987

2014

Volltextzugriff (PDF)

Rho kinase inhibition in diabetic nephropathy

Current opinion in nephrology and hypertension, 2011-01, Vol.20 (1), p.77-83

Komers, Radko

2011

Volltextzugriff (PDF)

MO255: Sparsentan Protects the Glomerular Basement Membrane and Glycocalyx, and Attenuates Proteinuria in a Rat Model of Focal Segmental Glomerulosclerosis (FSGS)

Nephrology, dialysis, transplantation, 2022-05, Vol.37 (Supplement_3)

2022

Volltextzugriff (PDF)

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. Reply

The New England journal of medicine, 2024-03, Vol.390 (12), p.1154-1155

2024

Volltextzugriff (PDF)

Altered Endothelial Nitric Oxide Synthase Targeting and Conformation and Caveolin-1 Expression in the Diabetic Kidney

Diabetes (New York, N.Y.), 2006-06, Vol.55 (6), p.1651-1659

2006

Volltextzugriff (PDF)

Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes

The Journal of clinical investigation, 2001-04, Vol.107 (7), p.889-898

2001

Volltextzugriff (PDF)

Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy

Expert review of clinical immunology, 2024-06, Vol.20 (6), p.571-576

2024

Volltextzugriff (PDF)

R ho kinase inhibition in diabetic kidney disease

British journal of clinical pharmacology, 2013-10, Vol.76 (4), p.551-559

Komers, Radko

2013

Volltextzugriff (PDF)

Status of current trials and potential future trials with sparsentan

Expert opinion on emerging drugs, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-3

2023

Volltextzugriff (PDF)

MO209: Baseline Characteristics of Adults Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan For the Treatment of Immunoglobulin A Nephropathy (PROTECT)

Nephrology, dialysis, transplantation, 2022-05, Vol.37 (Supplement_3)

2022

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(118)

Sprache

Englisch
(117)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Life Sciences & Biomedicine
(66)
Animals
(49)
Humans
(34)
Male
(34)
Urology & Nephrology
(30)
Rats
(29)
Biological And Medical Sciences
(19)
Rats, Sprague-Dawley
(19)
Medical Sciences
(17)
Diabetic Nephropathy
(16)
Glomerular Filtration Rate
(15)
Proteinuria
(15)
Blood Pressure - Drug Effects
(14)
Kidney - Metabolism
(14)
Kidney - Drug Effects
(13)
Physiology
(13)
Diabetes
(11)
Kidneys
(11)
Diabetic Nephropathies - Drug Therapy
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Rho kinase inhibition in diabetic nephropathy

miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7

Estrogen protects renal endothelial barrier function from ischemia-reperfusion in vitro and in vivo

An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis

Rho kinase inhibition in diabetic kidney disease

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis

Paradoxes of nitric oxide in the diabetic kidney

Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease

Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure

Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety

Enhanced phosphorylation of Na(+)-Cl- co-transporter in experimental metabolic syndrome: role of insulin

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

Pathophysiology of the Diabetic Kidney

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)

Renin inhibition in the treatment of diabetic kidney disease

Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment

Rho kinase inhibition in diabetic nephropathy

MO255: Sparsentan Protects the Glomerular Basement Membrane and Glycocalyx, and Attenuates Proteinuria in a Rat Model of Focal Segmental Glomerulosclerosis (FSGS)

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. Reply

Altered Endothelial Nitric Oxide Synthase Targeting and Conformation and Caveolin-1 Expression in the Diabetic Kidney

Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes

Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy

R ho kinase inhibition in diabetic kidney disease

Status of current trials and potential future trials with sparsentan

MO209: Baseline Characteristics of Adults Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan For the Treatment of Immunoglobulin A Nephropathy (PROTECT)

Suchergebnisse filtern